Can You Take BPC-157 With Tirzepatide or Semaglutide?

The medications this page covers:

Every price is all-in, covering medication, physician review, refill management and shipping, with no membership fee. GLP-1 prices are "from" prices because they are set by dose. Compounded medications are not FDA approved.

The question usually comes from someone on tirzepatide or semaglutide who has nausea, reflux or constipation and has read that BPC-157 is a "gut peptide." The live gut-health reference answers it directly: nausea, reflux and constipation on semaglutide or tirzepatide are a dose and titration question for the prescribing physician, not a reason to add a second vial.

There are three reasons for that answer:

1. The cause is known. GLP-1 stomach side effects come from slowed gastric emptying, and the approved labels state that most nausea, vomiting and diarrhea occur during dose escalation and decrease over time. Holding at the current strength, or stepping back, is the most powerful adjustment available, and it is made by your physician.
2. The BPC-157 gut research is a different question. It concerns protection of the gut lining against injury from NSAIDs and alcohol in animals. Nobody has studied whether it changes GLP-1 nausea, and there is no reason in the research to expect it to speed up or slow down a stomach that a GLP-1 is deliberately slowing.
3. A second vial can blur the picture. Some people report early nausea or light-headedness on BPC-157. Starting it while you are already queasy on a GLP-1 makes it harder for anyone to tell which medication is responsible.

What helps GLP-1 nausea, from portion size to meal timing, is in GLP-1 nausea: how to manage it. The full side-effect reference is tirzepatide side effects.

Where BPC-157 does appear alongside a GLP-1

BPC-157 is one of the four agents in the FUSION Blend, with MOTS-c, 5-Amino-1MQ and tesamorelin, which is positioned for use with or without a GLP-1. Prescribers using FUSION alongside a GLP-1 describe less of the gut discomfort patients associate with the GLP-1. That has not been tested in a trial, and it is a description of experience, not a finding.

The legitimate case for the pairing is an unrelated reason to take BPC-157 that happens to arise while you are on tirzepatide: most often a tendon, ligament or muscle problem, which is the area where the BPC-157 animal literature is strongest. A person on a weight program who starts training more often is a common example. In that case the two medications are treating different things, and the question is simply whether your physician is comfortable adding a second agent to your record.

Even then, some honest limits apply. For tendinopathy, progressive loading under a physiotherapist has human trial evidence, which BPC-157 does not. A complete rupture or displaced fracture is a surgical question. And BPC-157 is not a weight treatment and adds nothing known to tirzepatide's effect.

The BPC-157 figures are math from the vial concentration: 0.18 mL of a 1 mg/mL solution is 0.18 mg, and 5 mL divided by 0.18 mL gives 27 full doses. Both medications run on a 28-day refill cycle, one vial per fill.

Practical points:

• Two vials, two syringes. Never draw both into one syringe. Each label was calculated against its own vial's concentration, and neither describes a mixture.
• Rotate sites. Both go into the fat layer of the abdomen or thigh. On the day they coincide, use a different site for each.
• Keep the tirzepatide day fixed. Your weekly injection day stays the same; the daily BPC-157 dose fits around it.
• Refrigerate both. Both ship cold with ice packs, and beyond-use dating runs from first puncture. See how to store peptides.

How each product's vial is counted is in how long does a peptide vial last.

Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

Semaglutide acts at one incretin receptor, GLP-1, where tirzepatide acts at two, but both work through appetite and gastric emptying, and both cause the same family of stomach side effects. So the answer is identical: BPC-157 can be prescribed alongside semaglutide for an unrelated reason, the combination has not been studied, and BPC-157 is not a treatment for semaglutide's side effects. The comparison between the two GLP-1 medications is in semaglutide vs tirzepatide. The one firm rule: semaglutide and tirzepatide are never taken together.

1. Name the reason. "My Achilles has been sore since I started running" gives your physician something to work with. "My stomach is upset on tirzepatide" is a message to your care team about the GLP-1, not a BPC-157 request.
2. List everything. Include every medication and supplement, and anything you already take that contains BPC-157, such as the BPC-157 + TB-500 stack, GLOW, KLOW or FUSION, so nothing is duplicated.
3. Start one thing at a time. Avoid starting BPC-157 in the same week as a tirzepatide dose increase, so any change has one plausible cause.
4. Report what happens, including nothing. Your physician stays reachable through your account.

Your physician sets your directions after reviewing your intake, and every vial arrives with its directions printed on the label. More on combining is in can you take two peptides together and what peptides can you take with tirzepatide. Step-by-step guides: how to get BPC-157 prescribed and how to get tirzepatide prescribed.

Tirzepatide has a large human trial base in its approved form. BPC-157 has animal and cell research, early-phase human work for inflammatory bowel indications, and substantial prescribing experience, but no large randomised human trials. There is no study of the two together, no data on whether BPC-157 changes GLP-1 side effects, and no established interaction list for BPC-157 with anything. What can be said is narrower: the mechanisms are unrelated, the reasons to take each are different, and the pairing is a reasonable thing to discuss when there is a separate reason for BPC-157. It is not a stack that has been shown to work better than tirzepatide alone.

On regulation: BPC-157 was removed from Category 2 of the FDA's 503A bulk substances list on 15 April 2026, and in July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6 to recommend adding it to the 503A Bulks List. The FDA's final determination is pending.